Rockefeller Capital Management
CSTL icon

Rockefeller Capital Management’s Castle Biosciences CSTL Stock Holding History

Rockefeller Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Sell
87
-346
-80% -$7.71K ﹤0.01% 4419
2026
Q1 		$10.6K Buy
433
+346
+398% +$11.3K ﹤0.01% 3967
2025
Q4 		$3.38K Buy
+87
New +$2.81K ﹤0.01% 4184
2023
Q1 		– Sell
-4,294
Closed -$101K – 2378
2022
Q4 		$101K Buy
4,294
+154
+4% +$3.57K ﹤0.01% 2018
2022
Q3 		$107K Buy
4,140
+3,940
+1,970% +$110K ﹤0.01% 1950
2022
Q2 		$4K Sell
200
-22
-10% -$511 ﹤0.01% 3519
2022
Q1 		$9K Buy
222
+22
+11% +$909 ﹤0.01% 3097
2021
Q4 		$8K Hold
200
– – ﹤0.01% 3071
2021
Q3 		$13K Hold
200
– – ﹤0.01% 2764
2021
Q2 		$14K Sell
200
-1
-0.5% -$66 ﹤0.01% 2630
2021
Q1 		$13K Buy
+201
New +$15.1K ﹤0.01% 2470

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CSTL Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Castle Biosciences (CSTL) stake by 80% in Q2 2026, selling an estimated $7.71K and leaving 87 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4419.

Rockefeller Capital Management first reported a position in CSTL in Q1 2021 and has held it in 11 quarters since. The position peaked at $107K in Q3 2022. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Rockefeller Capital Management held 87 shares of Castle Biosciences worth $2.08K as of Q2 2026.
  • Rockefeller Capital Management sold 346 Castle Biosciences shares in Q2 2026, an estimated $7.71K.
  • Castle Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4419 holding.
  • Rockefeller Capital Management first reported a position in Castle Biosciences in Q1 2021 and has held it in 11 quarters since.
  • Rockefeller Capital Management's Castle Biosciences position peaked at $107K in Q3 2022.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.